Survivin expression in primary malignant melanoma of the esophagus.
Mamori
Satoshi
S
Kahara
Fumiaki
F
Ohnishi
Katsuhiro
K
Takeda
Akihiko
A
Higashida
Akihiro
A
Ashida
Cho
C
Yamada
Hajime
H
D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics; D001706:Biopsy; D015853:Cysteine Proteinase Inhibitors / Q000235:genetics; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D051034:Inhibitor of Apoptosis Proteins; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D008869:Microtubule-Associated Proteins / Q000235:genetics*; D008875:Middle Aged; D009285:Naphthoquinones / Q000627:therapeutic use; D000077022:Survivin; D016896:Treatment Outcome
D000970:Antineoplastic Agents; C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; D015853:Cysteine Proteinase Inhibitors; D007093:Imidazoles; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009285:Naphthoquinones; D000077022:Survivin; C523798:sepantronium